How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,272 results for

Instilling Eye Drops

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms

Study Details Study Description Go to Brief Summary: To determine whether a fall in tear osmolarity precedes improvement in symptoms and signs of dry eye in dry eye patients treated topically with 5% lifitegrast drops for 3 months. Condition or disease Intervention/treatment Phase Dry Eye Drug: Lifitegrast Phase 4 Detailed Description: A longitudinal, single-arm, prospective study will recruit up to 30 subjects with moderate to severe dry eye disease. Subjects will be >18 years of age, diagnosed (...) with moderate to severe dry eye (tear osmolarity > 320 mOsm/L and Visual Analog Scale (VAS) score > 40), willing to adhere to twice daily dosing (BID) and follow up visit schedule, have no history of ocular pathology / degeneration / allergy, not on any T-cell modulatory therapy, not have instilled any artificial tears within 2 hours of study visit, and not participating in any concurrent clinical trials. All subjects will complete an informed consent form indicating their voluntary participation

2016 Clinical Trials

162. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. (Full text)

Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. The SANSIKA study was conducted to assess the treatment effect of 0.1% cyclosporine A cationic emulsion (CsA CE) eye drops on signs and symptoms of patients with severe dry eye disease (DED).This was a multicenter, randomized, double-masked, 2-parallel-arm, 6-month phase III study with a 6-month open-label treatment safety follow-up. Patients with severe DED (...) CFS change from baseline to month 6 (-1.764 vs -1.418, p = 0.037). There was a reduction in ocular surface inflammation assessed by human leukocyte antigen DR expression in favor of CsA CE at month 6 (p = 0.021). The mean OSDI change from baseline was -13.6 with CsA CE and -14.1 with vehicle at month 6 (p = 0.858). The main adverse event was instillation site pain (29.2% vs 8.9% in the CsA CE and vehicle groups, respectively), and it was mostly mild.CsA CE was well-tolerated and effective

2016 European journal of ophthalmology Controlled trial quality: uncertain PubMed abstract

163. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study. (Full text)

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study. To evaluate the 1-year safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease compared with placebo.SONATA (Safety Of a 5.0% coNcentrATion of lifitegrAst ophthalmic solution) was a multicenter, randomized, prospective, double-masked, placebo-controlled phase 3 study (NCT01636206). Adults (≥18 years) with dry eye disease (Schirmer (...) test score ≥1 and ≤10 mm; corneal staining score ≥2.0) were randomized 2:1 to lifitegrast ophthalmic solution 5.0% or placebo twice daily for 360 days. The primary objective was percentage and severity of treatment-emergent adverse events (TEAEs). Secondary objectives were ocular safety measures: corneal fluorescein staining, drop comfort, best-corrected visual acuity, slit-lamp biomicroscopy, and intraocular pressure over 7 visits. Exploratory objectives included concentration of lifitegrast

2016 Cornea Controlled trial quality: predicted high PubMed abstract

164. Omega-3 fatty acid supplementation improves dry eye symptoms in patients with glaucoma: results of a prospective multicenter study. (Full text)

Omega-3 fatty acid supplementation improves dry eye symptoms in patients with glaucoma: results of a prospective multicenter study. The purpose of this study is to assess the effectiveness and tolerability of a dietary supplement with a combination of omega-3 fatty acids and antioxidants on dry eye symptoms caused by chronic instillation of antihypertensive eye drops in patients with glaucoma.A total of 1,255 patients with glaucoma and dry eye symptoms related to antiglaucoma topical medication (...) eye symptoms were statistically significant as compared to noncompliant patients.Dietary supplementation with Brudypio(®) may be a clinically valuable additional option for the treatment of dry eye syndrome in patients with glaucoma using antiglaucoma eye drops. These results require confirmation with an appropriately designed randomized controlled study.

2016 Clinical ophthalmology (Auckland, N.Z.) PubMed abstract

165. Exploring Immune Cell Signatures in Autoimmunity and Dry Eye Syndrome

and Cohorts Go to Outcome Measures Go to Primary Outcome Measures : Dry Eye Symptoms (SPEED Questionnaire) [ Time Frame: Day 0 ] Secondary Outcome Measures : Non-invasive Tear Break-up Time (NIKBUT) [ Time Frame: Day 0 ] Conjunctival Redness Grading with Oculus Keratograph 5M [ Time Frame: Day 0 ] Tear collection from Schirmers strip [ Time Frame: Day 0 ] To profile immune cells with EyePRIM membrane [ Time Frame: Day 0 ] Patients will be instilled with 1 drop of local anaesthetic. Conjunctival cells (...) Exploring Immune Cell Signatures in Autoimmunity and Dry Eye Syndrome Exploring Immune Cell Signatures in Autoimmunity and Dry Eye Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Exploring Immune

2016 Clinical Trials

166. Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye

Intervention/treatment Experimental: AGN-195263 Drug: AGN-195263 1 drop of AGN-195263 will be instilled in each eye twice daily. Placebo Comparator: Vehicle Drug: Vehicle 1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily. Outcome Measures Go to Primary Outcome Measures : Overall Ocular Discomfort Score (0 to 4 Scale; 0=None, 4=Very Severe) [ Time Frame: 6 month visit ] The overall ocular discomfort will be assessed on a questionnaire using a 0 to 4 scale on which 0=none, 1 (...) Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Topical

2016 Clinical Trials

167. Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

. Study Details Study Description Go to Brief Summary: The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID). Condition or disease Intervention/treatment Phase Dry Eye Syndromes Keratoconjunctivitis Sicca Drug: KPI-121 0.25% Ophthalmic (...) to successfully instill eye drops. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02813265 Sponsors and Collaborators Kala Pharmaceuticals, Inc. More Information Go to Layout table for additonal information Responsible Party: Kala Pharmaceuticals, Inc

2016 Clinical Trials

168. To Evaluate Eye Installation-Tear Free

091 Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule. Drug: SPF 50 Y49 091 (BAY 987516) 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye. Other: J & J baby shampoo, X46 046 (control) 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye. Experimental: SPF 50 X15 158 (...) Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule. Drug: SPF 50 X15 158 (BAY 987516) 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye. Other: J & J baby shampoo, X46 046 (control) 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye. Experimental: SPF 50 X15 160 Subjects

2016 Clinical Trials

169. Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

. Information provided by (Responsible Party): Kala Pharmaceuticals, Inc. Study Details Study Description Go to Brief Summary: The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID). Condition or disease Intervention/treatment Phase Dry Eye (...) of the Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02819284 Sponsors and Collaborators Kala Pharmaceuticals, Inc. More

2016 Clinical Trials

170. Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye

Intervention/treatment Experimental: AGN-195263 Drug: AGN-195263 1 drop of AGN-195263 will be instilled in each eye twice daily. Placebo Comparator: Vehicle Drug: Vehicle 1 drop of AGN-195263 vehicle(placebo) will be instilled in each eye twice daily. Outcome Measures Go to Primary Outcome Measures : Overall Ocular Discomfort Score (0 to 4 Scale; 0=None, 4=Very Severe) [ Time Frame: 6 month visit ] The overall ocular discomfort will be assessed on a questionnaire using a 0 to 4 scale on which 0=none, 1 (...) Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Topical

2016 Clinical Trials

171. Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome

: Allergan Pharmaceuticals, Ireland Active Comparator: Experimental: Patients with dry eye syndrome 3 40 Patients with dry eye syndrome Device: Systane Ultra Eye Drops Manufacturer: Alcon Pharma GmbH Outcome Measures Go to Primary Outcome Measures : Change in tear film thickness as measured with Optical Coherence Tomography (OCT) [ Time Frame: 10 weeks; at baseline, 10 minutes, 20 minutes, 40 minutes, 60 minutes, 120 minutes and 240 minutes after instillation of eye drops as well as 4 weeks and 8 weeks (...) . The aim of the present study is to assess the influence on tear film thickness of three different formulations of topical lubricants, in particular Thealoz Duo® Eye Drops, Optive® Eye Drops and Systane Ultra® Eye Drops in patients with moderate to severe dry eye disease. In addition, standard tests for dry eye syndrome, such as the ocular surface disease index (OSDI©), Schirmer I test, corneal fluorescein staining and determination of tear break up time (BUT) will be performed to compare the product

2016 Clinical Trials

172. Difference in the Frequency of Use of Lachrymal Substitutes in Patients With Moderate to Severe Dry Eye Syndrome

during the day + Thealoz Duo gel at night (1 drop before going to bed) for 7 days Other Name: Intervention 1 Device: Thealoz Duo gel Thealoz Duo gel during the day and at night for 7 days Other Name: Intervention 2 Outcome Measures Go to Primary Outcome Measures : Number of drops of Thealoz Duo® eye drops and Thealoz Duo® gel instilled during the day (patient diary) [ Time Frame: 4 weeks ] Number of drops of Thealoz Duo® eye drops and Thealoz Duo® gel instilled during the day during the observation (...) is usually reached by the use of artificial tears during the day. Nighttime relief is often achieved by substances known to be more adhesive to the ocular surface, such as gels. Condition or disease Intervention/treatment Phase Dry Eye Syndromes Device: Thealoz Duo eye drops and Thealoz Duo gel Device: Thealoz Duo gel Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 45 participants Allocation: Randomized Intervention

2016 Clinical Trials

173. Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes

Subjects will receive topical phenylephrine 2.5% eye drop instilled in one eye after all baseline measurements. Drug: Phenylephrine 2.5% Instilling phenylephrine 2.5% eye drop Outcome Measures Go to Primary Outcome Measures : Change in episcleral venous pressure [ Time Frame: baseline, 60 minutes ] Comparison using a two-sided t-test Secondary Outcome Measures : Change in intraocular pressure [ Time Frame: baseline, 60 minutes ] Comparison using a two-sided t-test Eligibility Criteria Go to Information (...) Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect of Topical

2016 Clinical Trials

174. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2

for the Treatment of Dry Eye : ARISE-2 Actual Study Start Date : November 2016 Actual Primary Completion Date : September 2017 Actual Study Completion Date : March 2018 Arms and Interventions Go to Arm Intervention/treatment Experimental: RGN-259 RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4 Drug: RGN-259 A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days Other Names: Tβ4 Thymosin Beta 4 Placebo (...) reported history of dry eye for at least 6 months Have a history of use or desire to use eye drops for dry eye symptoms within 6 months Exclusion Criteria: Have any clinically significant slit-lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters; Be diagnosed with an ongoing ocular infection

2016 Clinical Trials

175. The leaves of Diospyros kaki exert beneficial effects on a benzalkonium chloride–induced murine dry eye model (Full text)

treatment. Preservative-free eye drops were instilled in the positive-control group. The tear secretion volume (Schirmer's test), tear break-up time (BUT), and fluorescein score were measured on the ocular surface. BAC-induced corneal damage was tested with hematoxylin-eosin staining. Moreover, apoptotic cell death in the corneal epithelial layer was investigated with terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. The protein expression level of interleukin (...) The leaves of Diospyros kaki exert beneficial effects on a benzalkonium chloride–induced murine dry eye model In this study, the beneficial effects of the oral administration of ethanol extract of Diospyros kaki (EEDK) were tested on a mouse dry eye model induced by benzalkonium chloride (BAC).A solution of 0.2% BAC was administered topically to mouse eyes for 14 days, twice daily, to induce dry eye. Various concentrations of EEDK were administrated daily by oral gavage for 14 days after BAC

2016 Molecular vision PubMed abstract

176. Changes in central corneal thickness values after instillation of oxybuprocaine hydrochloride 0.4%. (Abstract)

(mean±SD). In each subject, one eye was treated with one drop of oxybuprocaine hydrochloride (HCl) and the fellow eye with one drop of normal saline (control). The SP-3000P CCT readings were first obtained before instillation (baseline) and monitored every 30 s after instillation of each eye drop for a period of 10 min.The mean baseline CCT for oxybuprocaine was 526±23 μm. Ten minutes after, it was 526±24 μm. In the control, the mean CCT was 526±27 μm, 10 min after it was 526±28 μm. The mean (...) variation in CCT measurement was -0.7±3.1 (5.5 to -6.8 μm, 95% CI) for oxybuprocaine and -0.6±4.1 μm (7.5 and -8.6 μm, 95% CI) for the fellow eyes (P>0.05). There was no significant variation among the 20 CCT columns for either oxybuprocaine or the control group (P>0.05 for both).One drop of topical oxybuprocaine 0.4% did not cause a significant change in CCT at up to 10 min following instillation. However, higher differences were observed at 2.30 min and 4.30 min after instillation.Copyright © 2012

2012 Contact lens & anterior eye : the journal of the British Contact Lens Association Controlled trial quality: uncertain

177. Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation

and Interventions Go to Arm Intervention/treatment Experimental: LE Gel A single dose LE Gel 0.5% administered into the study eye, tear samples collected at 6, 9, 12, and 24 hours after instillation by Schirmer strip to measures levels of LE in tears. Drug: LE Gel Single drop of LE Gel 0.5% administered to the study eye on visit 2 Other Name: Lotemax Outcome Measures Go to Primary Outcome Measures : Tear Fluid Levels [ Time Frame: 6 hours ] Following a single dose of LE gel 0.5% administered into the study eye (...) Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2012 Clinical Trials

178. Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears

that contains hyaluronate. Hyaluronate binds water and should help to maintain water on the eye. Objective: We plan to study the time course of possible changes in tear film osmolarity following instillation of an isotonic artificial tear containing hyaluronate. The investigators will use the TearLab, a new clinical instrument that has been developed to quickly and easily measure tear film osmolarity. Understanding how artificial tears affect tear film osmolarity over time can help doctors determine (...) efficacy and dosing schedules. The investigators will test the isotonic hyaluronate (Blink Contacts) artificial tears relative to normal saline solution. Hypothesis: The investigators should be able to measure a decrease in tear osmolarity over time following instillation due to the water-binding effect of hyaluronate artificial tears relative to a control (normal saline solution). Condition or disease Intervention/treatment Phase Dry Eye Drug: Artificial tears Not Applicable Detailed Description

2012 Clinical Trials

179. Added Benefits of Lachrymal Substitute Gel During the Night in Patients With Moderate to Severe Dry Eye Syndrome

by the use of artificial tears during the day. Nighttime relief is often achieved by substances known to be more adhesive to the ocular surface, such as gels. Condition or disease Intervention/treatment Phase Dry Eye Syndromes Device: Thealoz Duo Gel and Thealoz Duo eye drops Device: Thealoz Duo eye drops Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 45 participants Allocation: Randomized Intervention Model: Crossover (...) and then cross over to intervention 2 Device: Thealoz Duo Gel and Thealoz Duo eye drops Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day) Other Name: Intervention 1 Device: Thealoz Duo eye drops Thealoz Duo eye drops during the day (4 to 6 drops per day) Other Name: Intervention 2 Experimental: Patients with dry eye syndrome 2 20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1

2015 Clinical Trials

180. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1

for the Treatment of Dry Eye: ARISE-1 Study Start Date : September 2015 Actual Primary Completion Date : June 2016 Actual Study Completion Date : July 2016 Arms and Interventions Go to Arm Intervention/treatment Experimental: High Dose RGN-259 High dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4 Drug: RGN-259 A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days Other Names: Tβ4 Thymosin Beta 4 (...) Placebo Comparator: Placebo It is composed of the same excipients as RGN-259 but does not contain Tβ4 Drug: Placebo It is composed of the same excipients as RGN-259 but does not contain Tβ4 Other Name: Vehicle Control Experimental: Low Dose RGN-259 Low dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4 Drug: RGN-259 A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days Other Names: Tβ4

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>